Alterity Therapeutics Receives Positive Regulatory Feedback Following Type C Meeting With FDA Regarding Planned Phase 3 Development Program For ATH434 In MSA

Benzinga Newsdesk www.benzinga.com Positive 94.8%

Neg 0% Neu 0% Pos 94.8%

Comments

No comments yet. Be the first!